Membrane Proteome Array

De-risk and deorphan antibody programs by choosing the right lead molecule

What does your antibody bind?

Off-target drug binding can cause mild to serious side effects or even death. We developed the Membrane Proteome Array as the largest array of membrane proteins yet assembled for antibody specificity profiling and deorphaning.

What makes our MAb profiling approach unique?

We screen the largest human membrane protein library ever assembled using flow cytometry and unfixed cells for high-sensitivity detection, resulting in the highest success rates
 Membrane Proteome ArrayCell MicroarrayProtein Microarray
Size (unique proteins)5,3004,5003,800
Binding conditions unfixed cellsfixed cellscell lysate
Detection methodflow cytometryimmuno-fluorescenceimmuno-fluorescence
Hit validationdilution binding curveadditional service western blot
Speed4 weeks8 weeks3 weeks
Source: Competitor Website

“The team at IM is very scientifically engaged and responsive, and have an excellent turnaround time. The MPA allowed us to move forward with our targeted molecules with confidence of their specificity.”

- SVP RESEARCH AND DEVELOPMENT, CLINICAL STAGE BIOTECH

Why is the Membrane Proteome Array so successful?

  • Largest library for cell-based profiling of full-length membrane proteins - includes >95% of the membrane proteome
  • Flow cytometry for high-sensitivity detection in unfixed human cells
  • Cell-based platform ensures native protein conformations and post-translational modifications

How can the Membrane Proteome Array help you?

Specificity Profiling

We screen your antibody to determine its membrane proteome binding profile, identifying target and off-target interactions

Case Study: Learn more about how the MPA can de-risk your antibody discovery project

Antibody Deorphaning

We screen your antibody of unknown specificity to identify which protein(s) on the MPA your antibody binds

Case Study: Learn more about how the MPA can deorphan your antibodies

Phenotypic Target Discovery

We partner with you to discover new therapeutic targets using high-throughput, cell-based functional assays on our MPA library

Case Study: Learn more about how we use the MPA to discover novel therapeutic targets

What to Expect:

  1. You send us 500µg of your antibody
  2. We determine appropriate detection conditions
  3. We screen your antibody on the Membrane Proteome Array
  4. We validate any identified target protein(s) in a titration binding experiment
  5. We send you a final report within 4 weeks with a full analysis and publication-quality figures

“We have been very pleased with the data that we obtained from the Membrane Proteome Array platform. This showed that our antibodies recognize only their select target, and not the over 5,000 other membrane proteins in their panel.”

-MARIA GONZALEZ-PAJUELO, CSO, FAIRJOURNEY BIOLOGICS

Frequently Asked Questions

1What is the turnaround time for a Membrane Proteome Array project?
A typical MPA project takes 4 weeks from receipt of your antibodies.
2How does a Membrane Proteome Array project work?

The Membrane Proteome Array uses the largest membrane protein library ever assembled, flow cytometry, and unfixed cells for high-sensitivity detection, resulting in the broadest screens and the highest success rates. A typical project involves:

      1. You send us 500µg of each antibody that you would like screened
      2. We optimize conditions for detecting antibody binding in our high-throughput system
      3. We screen your antibodies on the Membrane Proteome Array under optimized conditions
      4. We confirm all identified targets in a second flow cytometry titration experiment
      5. You receive a detailed report within 4 weeks containing the membrane protein binding profiles of your antibodies, the identity of validated targets, and publication-quality figures
3What are the deliverables that I will receive upon completion of a project?
You will receive a detailed report containing the binding profiles of your antibodies and results from a second validation screen (antibody titration screen) on any identified targets. The report contains publication-quality figures. Additional publication, patent, and IND filing support is available on request.
4What binding conditions do you use for screening the Membrane Proteome Array?
The MPA is very flexible regarding screening conditions. Typically, we screen under unfixed conditions, but can use permeabilizing or even serum-free conditions if needed. We will discuss the best conditions for your antibodies with you at the start of your project.
5How do you validate your hits?
Hits are validated by testing serial dilutions of your antibodies for binding to cells over-expressing identified target(s) in a second flow cytometry experiment. This validation screen is included as part of every project.

Ready to Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let's talk about how we can help you.
Or call (215) 966-6061